DiaMedica Therapeutics (DMAC) Total Debt (2017)
DiaMedica Therapeutics' (DMAC) quarterly Total Debt came in at $84000.0 in Q4 2017.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Total Debt (2017) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Total Debt for 1 consecutive years, with $84000.0 the latest figure, recorded in Q4 2017.
- For the quarter ending Q4 2017, Total Debt changed N/A year-over-year to $84000.0; the trailing twelve-month figure through Dec 2017 stood at $84000.0 (changed N/A YoY), and the FY2017 full-year result was $84000.0, changed N/A from the prior year.
- Total Debt held at $84000.0 in Q4 2017 per DMAC's latest filing.
- Across five years, Total Debt topped out at $84000.0 in Q4 2017 and bottomed at $84000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.17 Bn | 193.18 Bn | 7.24 Bn | 62.75 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 28.66 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.74 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.28 Bn | 48.14 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 8.09 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | - |
| 10 | DiaMedica Therapeutics | 346.54 Mn | 346.54 Mn | - | - |